Advertisement

Low-Dose Radioiodine Therapy in Well-Differentiated Thyroid Carcinoma

  • Zehra Özcan
  • Ülkem Yararbaş
Chapter

Abstract

Thyroid carcinomas are usually diagnosed in small sizes and accepted as low-risk disease without disease-related mortality. However, there has been still controversy regarding the optimal management of differentiated thyroid carcinoma both in surgical technique and the use of radioactive iodine ablation. Moreover, there is also uncertainty about what activity should be administered for ablative purposes. In the current case, after completing almost 7 years of clinical follow-up without evidence of disease recurrence, low-dose radioactive ablation in thyroid cancer patients is discussed under the relevant literature.

Keywords

Thyroid cancer Radioactive ablation American Thyroid Association Management guidelines 

References

  1. 1.
    Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, et al. American Thyroid Association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without ınvasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:481–3.  https://doi.org/10.1089/thy.2016.0628.CrossRefPubMedGoogle Scholar
  2. 2.
    Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroidology. 1997;7:265–71.CrossRefGoogle Scholar
  3. 3.
    Goldsmith SJ. To ablate or not to ablate: ıssues and evidence ınvolved in 131I ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma. Semin Nucl Med. 2011;41:96–104.CrossRefGoogle Scholar
  4. 4.
    Gulec S, Kuker R. Radioactive iodine remnant ablation: the beta-knife completion thyroidectomy. Mol Imaging Radionucl Ther. 2017;26(Suppl 1):16–23.  https://doi.org/10.4274/2017.26.suppl.03.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Haymart MR, Esfandiari NH, Stang MT, Sosa JA. Controversies in the management of low-risk differentiated thyroid cancer. Endocr Rev. 2017;38:351–78.  https://doi.org/10.1210/er.2017-00067.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Blumhardt R, Wolin EA, Phillips WT, Salman UA, Walker RC, Stack BC Jr, et al. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review. Endocr Relat Cancer. 2014;21:R473–84.  https://doi.org/10.1530/ERC-14-0286.CrossRefPubMedGoogle Scholar
  7. 7.
    Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, Wang H. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J Clin Endocrinol Metab. 2013;98:1353–60.  https://doi.org/10.1210/jc.2012-3682.CrossRefPubMedGoogle Scholar
  8. 8.
    Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun. 2012;33:275–82.  https://doi.org/10.1097/MNM.0b013e32834e306a.CrossRefPubMedGoogle Scholar
  9. 9.
    Caglar M, Bozkurt FM, Akca CK, Vargol SE, Bayraktar M, Ugur O, et al. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Nucl Med Commun. 2012;33:268–74.  https://doi.org/10.1097/MNM.0b013e32834ec5d6.CrossRefPubMedGoogle Scholar
  10. 10.
    Kukulska A, Krajewska J, Gawkowska-Suwińska M, Puch Z, Paliczka-Cieslik E, Roskosz J, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res. 2010;31:9.  https://doi.org/10.1186/1756-6614-3-9.CrossRefGoogle Scholar
  11. 11.
    Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, et al. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Thyroid. 2014;24:820–5.  https://doi.org/10.1089/thy.2013.0362.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.  https://doi.org/10.1056/NEJMoa1109589.CrossRefPubMedGoogle Scholar
  13. 13.
    Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.  https://doi.org/10.1056/NEJMoa1108586.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang C, Zhao T, Li H, Gao W, Lin Y. Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension. Nucl Med Commun. 2017;38:366–71.  https://doi.org/10.1097/MNM.0000000000000666.CrossRefPubMedGoogle Scholar
  15. 15.
    Rosário PW, Calsolari MR. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Thyroid. 2014;24:826–31.  https://doi.org/10.1089/thy.2013.0479.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Zehra Özcan
    • 1
  • Ülkem Yararbaş
    • 1
  1. 1.Ege University School of Medicine, Department of Nuclear MedicineIzmirTurkey

Personalised recommendations